Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 0.89 |
| ▸ | ESR1 | P03372 | 16/20 | 0.89 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926652 | 0.94 | ESR2 (1.00) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL13958285 | 0.88 | ESR1 (0.70) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL19844982 | 0.87 | ESR1 (0.86) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL28226426 | 0.81 | ESR1 (0.70) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL38659424 | 0.81 | ESR1 (0.70) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL7858240 | 0.80 | ESR1 (0.69) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL16982202 | 0.80 | ESR1 (0.74) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL516421 | 0.79 | ESR1 (0.90) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL9938410 | 0.79 | ESR2 (0.71) | ESR2ESR1HSD17B1HSD17B2FGFR1 | |
| SCHEMBL1815385 | 0.78 | ESR1 (0.67) | ESR2ESR1HSD17B1HSD17B2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR2 5/4885ESR1 4/4885HSD17B1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.